Search clinical trials for: CP-690,550 (tasocitinib)

Total 741 results

Pfizer

Completed

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Hungary
Pfizer

Terminated

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Ulcerative Colitis

Spain, United States, Korea, Republic of, Serbia, Canada, Poland, Japan, France, New Zealand, South Africa, Germany, Slovakia, Hungary, Belgium, Czechia, Italy, Netherlands, Russian Federation, Ukraine, United Kingdom
Pfizer

Completed

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Plaque Psoriasis

United States
Pfizer

Completed

A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (OCTAVE)

Ulcerative Colitis

United States, Spain, Canada, Denmark, United Kingdom, France, Australia, Belgium, Israel, Germany, Korea, Republic of, Slovakia, Taiwan, Poland, New Zealand, Japan, Estonia, Hungary, Netherlands, Serbia, South Africa, Czech Republic and more
Pfizer

Completed

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

Healthy

Singapore
Pfizer

Completed

A Study Of CP-690,550 In Stable Kidney Transplant Patients

Kidney Transplant

United States
Pfizer

Completed

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Canada, Germany, Colombia, Hungary, Japan, Mexico, Poland, Serbia, Taiwan, Ukraine
Pfizer

Completed

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Canada, Poland, Serbia, Germany, Ukraine, Taiwan, Mexico, Colombia, Hungary, Puerto Rico
Pfizer

Active, not recruiting

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States, Spain, Belgium, Canada, India, Turkey, Australia, Mexico, South Africa, Germany, China, Poland, Slovakia, Israel, Hungary, Argentina, Brazil, Russian Federation, Ukraine, United Kingdom, Italy, Costa Rica
Pfizer

Completed

CP-690-550 Ointment For Chronic Plaque Psoriasis

Psoriasis

United States, Canada
Pfizer

Completed

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Psoriasis

Japan
Pfizer

Completed

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Costa Rica, Czech Republic, Germany, Croatia, Canada, Korea, Republic of, Spain, Bosnia and Herzegovina, Australia, Bulgaria, Mexico, Slovakia, Poland, Philippines, Chile, Denmark, Dominican Republic, Finland, T... and more
Pfizer

Completed

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Denmark, Slovakia, Canada, Australia, Argentina, Bulgaria, Netherlands, United Kingdom, Brazil, Finland, Greece
Pfizer

Completed

Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

Hemodialysis | End-Stage Renal Disease

United States
Pfizer

Completed

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Insufficiency

United States
Pfizer

Completed

Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis (OCTAVE)

Ulcerative Colitis

United States, Spain, Canada, Denmark, France, Australia, Belgium, Korea, Republic of, Hungary, Israel, Germany, Slovakia, Taiwan, Netherlands, Poland, New Zealand, United Kingdom, Japan, Austria, Estonia, Czechia, South Africa, Ukr... and more
Pfizer

Completed

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

Crohn's Disease

Netherlands, United States, Hungary, Belgium, Czech Republic, Italy, South Africa, Spain, United Kingdom, Slovakia, Poland, France
Pfizer

Terminated

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Spain, Korea, Republic of, Taiwan, Canada, Poland, Belgium, Denmark, Germany, Serbia, United Kingdom, France, Czechia, Hungary, Mexico, Colombia, Russian Federation, Croatia, Singapore, Australia, Austria, Slovakia, S... and more
Pfizer

Completed

Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

Renal Impairment

United States
Pfizer

Completed

Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550

Arthritis, Rheumatoid

United States, Czech Republic, Korea, Republic of, Mexico, Italy, India, Slovakia, Poland, Japan, Dominican Republic, Finland, Puerto Rico, Spain, Argentina, Bulgaria, Hungary, Brazil, Greece, Canada, Ukraine, Chile
Pfizer

Completed

Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers

Healthy

Singapore
Pfizer

Completed

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

Dry Eye Syndromes

United States
Pfizer

Completed

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Crohn's Disease

Korea, Republic of, United States, Spain, Netherlands, Australia, Israel, Canada, Czechia, Japan, Germany, Hungary, Austria, Bulgaria, Greece, South Africa, Ukraine, France
Pfizer

Completed

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Crohn's Disease

United States, Spain, Israel, Netherlands, Australia, Canada, Japan, Germany, Korea, Republic of, Hungary, Austria, Bulgaria, Czech Republic, Greece, South Africa, Ukraine, France
Pfizer

Completed

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Canada
Pfizer

Completed

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis

Psoriasis

Korea, Republic of, Taiwan, China
Pfizer

Completed

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Spain, Korea, Republic of, Taiwan, China, France, Belgium, Denmark, Bulgaria, Czechia, Hungary, India, Slovakia, Croatia, Turkey, Mexico, Canada, Germany, Argentina, Poland, Puerto Rico, Malaysia, Brazil, Australia, Romania, United Kingdom and more
Pfizer

Completed

Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan

Arthritis, Rheumatoid

Japan
Pfizer

Completed

CP-690,550 Pharmacokinetics In Healthy Chinese Subjects

Healthy

China
Pfizer

Completed

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Czech Republic, Germany, Croatia, Italy, Korea, Republic of, Slovakia, Bulgaria, Brazil, Chile, Romania, Greece, Ukraine, Hungary, Mexico
Pfizer

Completed

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (OCTAVE)

Ulcerative Colitis

United States, Spain, Canada, Israel, Australia, Germany, Serbia, Japan, Denmark, France, Hungary, Poland, United Kingdom, Belgium, New Zealand, Netherlands, Austria, Colombia, Croatia, Czech Republic, Estonia, Italy, Latvia, Romania, Russian... and more
Pfizer

Completed

A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Germany, Korea, Republic of, Spain, Czech Republic, Mexico, Poland, Russian Federation
Pfizer

Completed

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

Korea, Republic of, Canada, United States, Spain, Netherlands, Australia, Israel, Croatia, Japan, Germany, Hungary, Bulgaria, Austria, Czech Republic, France, Greece, South Africa, Ukraine
Pfizer

Completed

A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

Dry Eye Syndromes

Korea, Republic of, Japan
Pfizer

Completed

A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (OCTAVE)

Ulcerative Colitis

Korea, Republic of, United States, United Kingdom, Australia, Austria, Denmark, Canada, Israel, Germany, Belgium, Taiwan, Latvia, Spain, Poland, New Zealand, Hungary, Netherlands, France, Estonia, Serbia, South Africa, Slovakia, Cro... and more
Pfizer

Completed

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Rheumatoid Arthritis

Japan
Pfizer

Completed

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Brazil, Germany, India, Czech Republic, Russian Federation, Bulgaria, Ukraine, Colombia, Philippines, Chile, Dominican Republic, Mexico, Poland, Puerto Rico, Malaysia
Pfizer

Completed

A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers

Healthy Volunteers

Singapore
Pfizer

Completed

Topical CP-690,550 For Chronic Plaque Psoriasis

Psoriasis

United States, Canada
Pfizer

Completed

Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)

Juvenile Idiopathic Arthritis

United States, Slovakia, Poland, Germany
Pfizer

Withdrawn

A Study Of Tasocitinib In Dry Eye Subjects

Keratoconjunctivitis Sicca
Pfizer

Completed

A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers

Arthritis, Rheumatoid

United States
Pfizer

Completed

Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

Rheumatoid Arthritis

United States, Germany, Italy, Spain, Canada, Belgium, Slovakia, Brazil, Mexico
Pfizer

Completed

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

Arthritis, Rheumatoid

United States, Spain, Colombia, Finland, Sweden, Croatia, China, Germany, Australia, Mexico, Poland, Slovakia, Russian Federation, Chile, Denmark, Thailand, United Kingdom, Venezuela, Malaysia, Greece
Pfizer

Completed

A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form

Healthy

Singapore
Pfizer

Completed

CP-690,550 and Midazolam Drug-Drug Interaction Study

Healthy Volunteer

United States
Pfizer

Completed

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

Belgium, Spain, Germany, France, Hungary, Russian Federation, Singapore, Argentina, Austria, Bosnia and Herzegovina, Bulgaria, Chile, Colombia, Croatia, Czechia, Denmark, Hong Kong, Israel, Korea, Republic of, Netherlands, Poland, Slovaki... and more
Pfizer

Completed

Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers

Rheumatoid Arthritis

Belgium
Pfizer

Completed

Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

Healthy

United States

Search clinical trials for: CP-690,550 (tasocitinib)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations